{
"author": {
"name": "Anshul Mangal",
"webUrl": "/author/profile/anshul-mangal/",
"description": "",
"imageLarge": "https://secure.gravatar.com/avatar/f16d6fc2845f417ea0e93a3f2b6cd37d?s=136&d=mm&r=g",
"estimate": 1,
"social": [],
"articles": [
{
"uri": "/2022/02/11/a-shared-opportunity-the-future-of-cell-and-gene-therapy/",
"title": "A shared opportunity: The future of cell and gene therapy",
"byline": "Anshul Mangal and Philip Cyr, Sr.",
"kicker": "Commentary",
"prettyDate": "February 11, 2022",
"timeToRead": "7 minute",
"image": {
"uri": "https://images.benefitspro.com/contrib/content/uploads/sites/412/2018/11/GeneEditing.jpg",
"width": "616",
"height": "372"
},
"authors": [
{
"webUrl": "/author/profile/anshul-mangal/",
"name": "Anshul Mangal"
},
{
"webUrl": "/author/profile/philip-cyr-sr/",
"name": "Philip Cyr, Sr."
}
],
"kickerNode": [
{
"uri": "/commentary/",
"sectionName": "Commentary"
}
],
"summary": "The commercialization of cell and gene therapies raises several complex conversations and questions for employers and payers.",
"body": null
}
]
}
}